Phospholipid Bilayers Catalyze Protein Refolding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to address protein misfolding and aggregation in neurodegenerative diseases, such as Alzheimer's, are limited in effectively inhibiting and reversing the formation of amyloid fibrils, with existing methods being stoichiometric and not catalytic, and lacking in degrading pre-formed fibrils, which are often toxic and difficult to reverse.
Innovation Solution
The use of homogenous and heterogenous phospholipid bilayers, specifically DOPC and DOPG, to catalytically promote protein refolding, increase protein stability, and inhibit or reverse the formation of protein aggregates by degrading pre-formed fibrils into soluble protofilaments, thereby preventing further aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stoichiometric approaches are used to inhibit amyloid fiber formation, then some inhibition effect is achieved, but the method is not catalytic and requires large amounts of therapeutic agents
Solution Approach 1:
The invention changes the fundamental parameter of the therapeutic mechanism from stoichiometric binding to catalytic action. Phospholipid bilayers are used to create a microenvironment that catalyzes protein refolding, allowing small amounts of the therapeutic agent to regenerate and act on multiple misfolded proteins, thereby reducing the quantity of substance needed while maintaining reliable inhibition of amyloid fiber formation
Solution Approach 2:
The phospholipid bilayer system enables self-service by creating a catalytic cycle where the bilayer promotes protein refolding without being consumed. The system regenerates active therapeutic components through the catalytic refolding process, allowing the therapeutic agent to continuously inhibit amyloid fiber formation without requiring large stoichiometric amounts
2Reliability
If existing methods are used to inhibit amyloid fiber formation, then early stage formation is slowed, but pre-formed fibrils cannot be degraded
Solution Approach 1:
The phospholipid bilayer system performs multiple functions: it catalyzes protein refolding to prevent new amyloid fiber formation, and simultaneously degrades pre-formed fibrils through the same catalytic mechanism. This multi-functionality allows a single therapeutic approach to address both early-stage prevention and late-stage degradation, enhancing adaptability across different disease stages
Solution Approach 2:
The phospholipid bilayer acts as an intermediary that facilitates protein refolding and fibril degradation. The bilayer creates a controlled microenvironment that mediates the interaction between therapeutic agents and misfolded proteins, enabling both inhibition of new fiber formation and degradation of pre-formed fibrils through catalytic refolding mechanisms
3Productivity
If lipid bilayers are used to promote protein refolding, then catalytic promotion of refolding is achieved, but the mechanism remains partially understood
Solution Approach 1:
The phospholipid bilayer system enables self-service by creating a catalytic cycle where the bilayer promotes protein refolding without being consumed. The system regenerates active therapeutic components through the catalytic refolding process, allowing the therapeutic agent to continuously inhibit amyloid fiber formation without requiring large stoichiometric amounts
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described method effectively inhibits the formation and degrades pre-formed amyloid fibrils, reducing their toxicity and preventing further aggregation, offering a potential therapeutic strategy for neurodegenerative diseases by promoting protein refolding and stabilization.
Implementation Method 1
phospholipid bilayers catalytically promote protein refolding
Implementation Method 2
phospholipid bilayers catalytically promote protein refolding, increase protein stability, prevent loss of protein secondary structure
Implementation Method 3
degrading pre-formed fibrils into soluble protofilaments
Implementation Method 4
degrading pre-formed fibrils into soluble protofilaments
Implementation Method 5
increase protein stability, prevent loss of protein secondary structure
Implementation Method 6
increase protein stability, prevent loss of protein secondary structure
Data Source
AI summary
Here, the present inventors describe novel methods and compositions to reduce protein misfolding, the formation of protein aggregates, as well as the degradation of previously formed protein aggregates, for example by separating fibrils back into protofilaments. Additional aspects of the invention include therapeutic uses of lipid bilayers to rescue misfolded proteins in Alzheimer's and other protein misfolding diseases.